Article, see p 2241 R are are the approaches that have changed our understanding of coronary artery disease as has fractional flow reserve (FFR). After extensive animal and human validation work and hypothesis-generating observational studies, 1 larger randomized trials with a superiority design have reshaped our therapeutic strategies in stable coronary artery disease and, albeit to a lesser extent, of acute coronary syndromes. In a nutshell: (1) stenoses with an FFR >0.80 do not benefit from revascularization, not even the nonculprit vessels in patients with acute coronary syndromes 2,3 ; (2) patients with ≤1 stenosis with an FFR ≤0.80 are better off with contemporary percutaneous coronary intervention than with medical therapy 4 ; (3) the angiographic 50% diameter stenosis is a battered standard to define coronary artery disease, risk stratify patients, or guide therapy 5, 6 ; (4) performing FFR during diagnostic angiography modifies about half of the revascularization decisions 7 ; and (5) there is a risk continuum for FFR over the entire range of stenosis severity. 8, 9 Therefore, one might wonder what an observational database could add to this knowledge. The results of the IRIS-FFR registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve) published in this issue of Circulation 10 largely confirm the points listed here, but this confirmation is welcome for several reasons.
R
are are the approaches that have changed our understanding of coronary artery disease as has fractional flow reserve (FFR). After extensive animal and human validation work and hypothesis-generating observational studies, 1 larger randomized trials with a superiority design have reshaped our therapeutic strategies in stable coronary artery disease and, albeit to a lesser extent, of acute coronary syndromes. In a nutshell: (1) stenoses with an FFR >0.80 do not benefit from revascularization, not even the nonculprit vessels in patients with acute coronary syndromes 2, 3 ; (2) patients with ≤1 stenosis with an FFR ≤0.80 are better off with contemporary percutaneous coronary intervention than with medical therapy 4 ; (3) the angiographic 50% diameter stenosis is a battered standard to define coronary artery disease, risk stratify patients, or guide therapy 5, 6 ; (4) performing FFR during diagnostic angiography modifies about half of the revascularization decisions 7 ; and (5) there is a risk continuum for FFR over the entire range of stenosis severity. 8, 9 Therefore, one might wonder what an observational database could add to this knowledge. The results of the IRIS-FFR registry (Interventional Cardiology Research Incooperation Society Fractional Flow Reserve) published in this issue of Circulation 10 largely confirm the points listed here, but this confirmation is welcome for several reasons.
HIGH-QUALITY DATA
The quality of the prospective IRIS-FFR registry appears superior and illustrates that trials and registries are complementary approaches. The number of patients is markedly larger than in previous randomized trials on clinical outcome of patients treated on the basis of applied coronary physiology. In addition, virtually all consecutive patients of this South Korean cooperative research network were included. This provides a particularly representative patient population, more than in most randomized trials, in which cherry picking, slow recruitment, and sometimes misleading trial design prevent them from truly answering the clinical questions. The real-life aspect of IRIS-FFR is reflected by the high proportion of patients with multivessel disease, including left main stenosis and a reasonable level of acute coronary syndrome for a coronary physiology registry. Finally, and quite unique for a registry, all cases were monitored, and events were adjudicated by an external research organization, thus limiting the risk of underreporting of events uniformly associated with registries. Therefore, this report represents a complete, accurate, and consistent picture of patient outcomes after FFR-guided decision making.
NUANCED ADDITIONAL INFORMATION AND LIMITATIONS
Beyond the main confirmatory message, the large data set provides a wealth of clinically important information not necessarily discussed by the authors. It is important to note that the rate of complications related to the measurement are reassuringly low in the hands of operators, who for many years have considered that gaining physiological information is a natural prolongation of the angiogram.
In Figure 6 of the main article, Ahn et al 10 show 2 FFR cutoff values: the first, at 0.79, for MACE, and the second, at 0.64, for death or myocardial infarction. These values are derived from the estimate of each individual stenosis to be associated with MACE or death/myocardial infarction after deferral or revascularization, respectively. This figure should not suggest the use of 2 different cutoff values for clinical decision making about revascularization. Rather, it should be seen as a further demonstration of the dose-intensity relationship between FFR and outcome: the lower the FFR, the worse the outcome.
The IRIS-FFR registry did not show any difference between revascularization and deferral for lesions with an FFR between 0.76 and 0.80. This finding confirms a recent report by Adjedj et al, 11 although the latter report found a strong trend in overall death or myocardial infarction favoring revascularization, especially in proximal coronary segments.
As mentioned by the authors, this study is "neither a randomized trial nor a natural history study." General recommendations for revascularization of lesions with an FFR <0.75 and for medical therapy in lesions with an FFR >0.80 were followed in the majority of cases. Hence, the outcome data are modulated by the therapeutic choice made for each individual lesion. Some patient-or lesion-related characteristics play a role in the therapeutic choice but are not necessarily accounted for by marginal Cox modeling. This is further complicated by the fact that the analysis was made at the lesion level, whereas almost half of the patients had multivessel disease. Some events cannot be related to 1 lesion. Fortunately, only 8% of events could not be clearly assigned to a given stenosis.
The present report by Ahn et al 10 does not provide data on the penetration rate of FFR (ie, the number of patients in whom the procedure is guided by FFR divided by the total number of procedures). Previous work from the same group 12 indicated a penetration rate between 40% and 50%. This likely represents the maximum reasonable achievable rate of FFR expressed per number of percutaneous coronary interventions.
PERSPECTIVES
Ahn and colleagues from the IRIS-FFR registry provide a top-quality, large-scale, real-world confirmation of the essential contributions of invasive pressure-derived FFR to our understanding of applied coronary physiology in patients with coronary artery disease. Daily practice tells us that there is no need to change the standard. 13 In contrast, this forms solid ground for further refining less invasive or noninvasive FFR approaches that are about to change the diagnostic workup of patients with chest pain. 14, 15 In conjunction with this FFR multimodality approach, the IRIS-FFR registry confirms that FFR has become to coronary physiology what ejection fraction is to left ventricular function. 
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